Topics

Pfizer's $225K Price for Heart Drug Tafamidis Slammed

11:53 EST 15 Jan 2020 | Medscape

The current price hinders access for those most likely to benefit and slows clinical advances in the management of ATTR-CM, a 'not-so-rare' condition, experts say.
Medscape Medical News

Original Article: Pfizer's $225K Price for Heart Drug Tafamidis Slammed

NEXT ARTICLE

More From BioPortfolio on "Pfizer's $225K Price for Heart Drug Tafamidis Slammed"

Quick Search